Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Ann DeWitt
AddedMar 31, 2024
UpdatedMay 1, 2026
Ann DeWitt

Ann DeWitt

Board Member, ImmuneXcite

Ann DeWitt's Career

ImmuneXcite
ImmuneXcite

Lexington, KY, US

Board Member· Board
Cellino
Cellino

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Ann DeWitt's Career

ImmuneXcite
ImmuneXcite
Series A$15.7M102007Lexington, KY, US
Board Member· Board

Leadership at ImmuneXcite

Eric FurfineEric FurfineBoard Member
Yaniv BejeranoYaniv BejeranoCo-Founder
Ifat Rubin-BejeranoIfat Rubin-BejeranoCo-Founder

Similar to ImmuneXcite

InfinimmuneInfinimmuneSan Francisco, CA, USAntibody Drugsest. 2022InfinimmuneSan Francisco, CA, US · est. 2022

Infinimmune: A biotech firm revolutionizing antibody drug development through a comprehensive platform.

Seed · $12M7
ExcelimmuneExcelimmuneWoburn, MA, USAntibody Treatmentsest. 2006ExcelimmuneWoburn, MA, US · est. 2006

Excelimmune, Inc.: A US-based biopharmaceutical firm developing therapeutic antibodies for various diseases.

Series A · $36M30
DecImmune TherapeuticsDecImmune TherapeuticsCambridge, MA, USBiotech Productsest. 2001DecImmune TherapeuticsCambridge, MA, US · est. 2001

DecImmune Therapeutics develops biotech products for acute inflammation and vascular injury treatment.

Seed · $8.4M7
ImmuneIDImmuneIDBoston, MA, USImmunology Therapeuticsest. 2020ImmuneIDBoston, MA, US · est. 2020

ImmuneID: A precision immunology firm targeting antibody interactions to combat immune diseases.

Series A · $67M48
Cellino
Cellino
Series A$97.5M892017Cambridge, MA, US
Board Member· Board

Leadership at Cellino

Nabiha SaklayenNabiha SaklayenCo-Founder
Marinna MadridMarinna MadridCo-Founder
Stan WangStan WangCo-Founder
Matthias WagnerMatthias WagnerCo-Founder

Similar to Cellino

Cell BioEnginesCell BioEnginesNew York City, NY, USCell Therapiesest. 2022Cell BioEnginesNew York City, NY, US · est. 2022

Cell BioEngines, Inc.: A clinical-stage biotech firm innovating cancer cures with scalable cell therapies.

Pre-Seed · $625k6
CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
CelviveCelvivePrinceton, NJ, USStem Cell Therapyest. 2011CelvivePrinceton, NJ, US · est. 2011

Celvive, Inc.: Pioneering regenerative medicine with a focus on neural regeneration since 2011.

Angel · $225k5
RhinoCyteRhinoCyteLouisville, KY, USStem Cell Treatmentsest. 2005RhinoCyteLouisville, KY, US · est. 2005

RhinoCyte: A leading provider of stem cell treatments, offering rewarding careers and a balanced work-life.

Angel · $4.7M2

Ann DeWitt's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Ann DeWitt

Michael SchraderMichael SchraderCo-Founder · Vaxess TechnologiesJim ConnollyJim ConnollyBoard Member · Vaxess TechnologiesRobert R. RuffoloRobert R. RuffoloBoard Member · Elicio TherapeuticsLivio ValentiLivio ValentiCo-Founder · MoriChrystyna Bedrij StecykChrystyna Bedrij StecykBoard Member · VaccinexKathryn KosudaKathryn KosudaCo-Founder · Vaxess Technologies